2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Autoimmune Disease
  5. Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is a chronic, complex autoimmune disease characterized by the immune system's abnormal attack on healthy tissues and organs, leading to widespread inflammation and multi-system involvement. It is the most common form of lupus, affecting various body systems including the skin, joints, kidneys, brain, and blood vessels. Key features include variable symptoms such as joint pain and swelling, butterfly-shaped facial rashes, fever, fatigue, and neurological manifestations like seizures or cognitive impairment. SLE is driven by a combination of genetic, epigenetic, and environmental factors, with periods of disease flares alternating with remissions. The disease can progress over time, potentially resulting in life-threatening complications such as nephritis or cardiovascular issues. Laboratory findings often include elevated erythrocyte sedimentation rate, presence of LE cells, and autoantibodies against nuclear and cytoplasmic antigens. Children may develop a more severe form known as childhood-onset SLE, highlighting the disease’s diverse clinical presentation and systemic impact.

Systemic Lupus Erythematosus (27):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-117287
    Deucravacitinib 1609392-27-9 99.93%
    Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation. Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
    Deucravacitinib
  • HY-P99168
    Anifrolumab 1326232-46-5 99.79%
    Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.
    Anifrolumab
  • HY-150095
    YE6144 3065657-02-2
    YE6144 free base is a selective prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 free base suppresses the disease course and is especially effective in remission maintenance in a mouse model of systemic lupus erythematosus (SLE). YE6144 free base can be used for SLE research.
    YE6144
  • HY-P9990
    Litifilimab 2407378-48-5 99.51%
    Litifilimab (BIIB059) is a humanized anti-BDCA2 IgG1 monoclonal antibody administered subcutaneously. Litifilimab can inhibit the production of type I interferons, cytokines and chemokines. Litifilimab can be used in the research of diseases such as systemic lupus erythematosus.
    Litifilimab
  • HY-P990091
    Riliprubart 2756228-76-7 99.90%
    Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Riliprubart
  • HY-P992101
    Aritinercept 3057276-00-0 99.90%
    Aritinercept (AUR-200) is a recombinant fusion protein targeting TNFSF13B/BAFF/CD257. Aritinercept neutralizes BAFF and APRIL (TNFSF13), reduces B cell proliferation, suppresses peripheral B cells, lowers serum immunoglobulins. Aritinercept reduces renal damage markers, decreases IFNγ, IL-17A, and anti-dsDNA autoantibodies, and improves survival in a mouse model of SLE. ritinercept can be used for the research of systemic lupus erythematosus.
    Aritinercept
  • HY-177277A
    (R)-HM5023507 1549740-86-4
    (R)-HM5023507 is a potential PI3K inhibitor. (R)-HM5023507 can be used for the research of cancer, inflammatory, allergic and autoimmune diseases and leukemia etc.
    (R)-HM5023507
  • HY-129442
    MNA 279 185915-32-6
    MNA 279 (X 910279) is an orally active, immunosuppressive malononitrilamide and A 771726 derivative. MNA 279 suppresses IgM and IgG antibody production. MNA 279 prevents the development of systemic lupus erythematosus (SLE)-like disease in mice. MNA 279 prolongs skin xenograft survival in a mouse-to-rat model.
    MNA 279
  • HY-P11072
    IRF5-CPP5 1601299-92-6 99.23%
    IRF5-CPP5 is a cytosolic peptide that selectively targeting human IRF5 wirh a Kd of 0.53 μM. IRF5-CPP5 disrupts IRF5 homodimerization and inhibits its nuclear translocation without altering IRF5 phosphorylation levels. IRF5-CPP5 inhibits proinflammatory cytokine (IL-6, IL-1β, TNF-α) production. IRF5-CPP5 can be used for the research of systemic lupus erythematosus.
    IRF5-CPP5
  • HY-P99877
    Efavaleukin alfa 2049067-94-7 ≥99.0%
    Efavaleukin alfa (AMG592) is a IL-2 mutein fragment crystallizable fusion protein. Efavaleukin alfa drives the selective expansion of regulatory T cells. Efavaleukin alfa is applicable to research related to systemic lupus erythematosus.
    Efavaleukin alfa
  • HY-164288
    TDI-6570 2287331-29-5 99.64%
    TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases.
    TDI-6570
  • HY-153701S
    Envudeucitinibum 2417135-66-9 99.56%
    Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases.
    Envudeucitinibum
  • HY-137978
    Ezurpimtrostat 1914148-72-3 99.37%
    Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders.
    Ezurpimtrostat
  • HY-178037
    TLR9 antagonist 1 3105410-45-2
    TLR9 antagonist 1 is a selective hTLR9 antagonist with an IC50 of 0.1 nM against hTLR9. TLR9 antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus.
    TLR9 antagonist 1
  • HY-P99893
    Rozibafusp alfa 2143449-47-0
    Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Rozibafusp alfa can be used for the research of systemic lupus erythematosus and other autoimmune diseases.
    Rozibafusp alfa
  • HY-P4155
    SSA antigenic peptide 99.37%
    SSA antigenic peptide is an antigenic peptide of Sjögren's syndrome-related antigen A (SSA). SSA antigenic peptide can be used for the research of systemic lupus erythematosus.
    SSA antigenic peptide
  • HY-P99529
    Valziflocept 1804910-11-9 99.00%
    Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE).
    Valziflocept
  • HY-P992394
    JNJ-55920839
    JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonal antibody and a selective Interferon α/ω neutralizer, with a Kd value of 0.9-10.7 pM against hIFNα and a Kd of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus.
    JNJ-55920839
  • HY-P992348
    DS-7011a
    DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE).
    DS-7011a
  • HY-182409
    TSI-13-48 2254006-84-1
    TSI-13-48 (HY-182409) is a TLR inhibitor with IC50 values of 3.02, 22.3, 26.5, and 26.6 μM against TLR9, TLR7, TLR2, and TLR4, respectively. TSI-13-48 can be used in research related to systemic lupus erythematosus, polymicrobial sepsis, and cerebral malaria.
    TSI-13-48